Comparison of 2-Week Versus 4-Week Dosing Intervals of Epoetin Beta Pegol on Erythropoiesis and Iron Metabolism in Hemodialysis Patients-Reference-Cited by-同舟云学术

Comparison of 2-Week Versus 4-Week Dosing Intervals of Epoetin Beta Pegol on Erythropoiesis and Iron Metabolism in Hemodialysis Patients

Published:2014-01-24 Issue:5 Volume:18 Page:414-420
ISSN:1744-9979
Container-title:Therapeutic Apheresis and Dialysis
language:en
Short-container-title:Ther Apher Dial

Author:

Morikami Yuki¹,Fujimori Akira¹,Okada Shioko¹,Kumei Mai¹,Mizobuchi Noriko²,Sakai Makoto²

Affiliation:

1. Blood Purification and Kidney Center; Konan Hospital; Kobe Japan

2. Department of Internal Medicine; Konan Hospital; Kobe Japan

Publisher

Wiley

Subject

Nephrology,Hematology

Reference20 articles.

1. Recombinant human erythropoietin: implications for nephrology;Eschbach;Am J Kidney Dis,1988

2. Greater potency of darbepoetin-alpha than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients;Shoji;Eur J Haematol,2013

3. Pharmacokinetics of C.E.R.A. (Continuous Erythropoietin receptor Activator) in Japanese Chronic Kidney Disease Patients on Dialysis;Hayashi;Jpn Pharmacol Ther,2010

4. Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients;Weinreich;Hemodial Int,2012

5. Monthly CERA treatment maintains stable hemoglobin levels in routine clinical practice of peritoneal dialysis patients;Gonzalez;Ren Fail,2013

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential effective treatment of shortening continuous erythropoietin receptor activator treatment interval combined with iron supplementation in hemodialysis patients;Journal of Pharmacological Sciences;2021-09

2. Comparison of the effects of weekly and biweekly intravenous CERA administration on erythropoiesis: A randomized controlled trial;The Journal of Clinical Hypertension;2021-01-22

3. Possible role of neocytolysis in anemia in hemodialysis patients with darbepoetin alfa or continuous erythropoietin receptor activator;Therapeutic Apheresis and Dialysis;2020-07-28

4. Misdistribution of iron and oxidative stress in chronic kidney disease;Free Radical Biology and Medicine;2019-03

5. Iron Metabolism in Chronic Kidney Disease Patients;CKD-Associated Complications: Progress in the Last Half Century;2019